In the early 2000s, 2C-I was sold in Dutch smart shops after the drug 2C-B was banned. In April 2008, 2C-I was also banned in the Netherlands, along with three other 2C-x phenethylamines previously sold in Dutch smartshops for short periods of time. During the same period, 2C-I also became available in powder form from several online vendors of research chemicals in the United States, Asia, and Western Europe.
It is often misrepresented as mescaline in US street sale of singular dosages, as it shares some level of similarity in psychological effect. Both chemicals are members of the psychedelic phenethylamine class of drugs, except 2C-I is an analog of mescaline in the 2C-x series. A major difference between the research chemicals in the 2C-x series and mescaline is a much greater potency by weight and thus also a steeper dose-response in the newer synthetic drugs. 2C-I's effective dosage range per milligram is approximately 10-fold less than mescaline.[medical citation needed] This means that a small carrier material, such as a small candy or pressed pill, is suitable for 2C-I. That type of small carrier material has an insufficiently small holding capacity to contain a large enough quantity of mescaline to produce a substantial psychoactive effect.
This section needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be removed.(May 2014)
The onset of effects occurs between one to two hours when taken orally, and 10–20 minutes when insufflated; lasting between 4 to 12 hours (depending on the dose) though some users have reported a duration of 16–18 hours.[medical citation needed] A shorter duration is typical for insufflated doses. The effects at small dosages (less than 12 mg) has been reported as more mental and less sensory than those of 2C-B. Users often report strong physical stimulation. Unpleasant physical side-effects including muscle tension, hypertensive crisis, overstimulation, nausea, vomiting, seizures have been reported. The incidence of unpleasant side effects is less commonly reported than with other closely related substituited phenethylamines such as 2C-T-2 and 2C-T-7 which also act as monoamine oxidase inhibitors and may have other action on amine reuptake. Visual effects of 2C-I exposure have been described by many users as iterating fractals, along with a more generalized shift in perception and/or cognition.
2C-I has been noted by several users to decrease in visual or psychedellic effects with repeated administration, and to increase in symptoms of hypertensive crisis. 2C-I is also known to degrade in heat, and though the degradation products are yet unclassified user reports of degraded 2C-I allege the absence of psychedellic affect. The degraded form has also been reported by several users to have an opposite affect on saliva production, inhibiting it almost entirely in some instances. This factor has been noted as particularly uncomfortable or dangerous, as the action of swallowing without a fluid buffer causes a vacuum to pull on the inner ear.
Drug prohibition laws
In December 2003, the European Council issued a binding order compelling all EU member states to ban 2C-I within three months.
Sveriges riksdag added 2C-I to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Mar 16, 2004, published by Medical Products Agency in their regulation LVFS 2004:3 listed as 4-jodo-2,5-dimetoxifenetylamin (2C-I).
^European Monitoring Centre for Drugs and Drug Addiction (2004). Report on the risk assessment of 2C-1, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs Office for Official Publications of the European Communities, p. 109. ISBN 9789291681815